Fosfluconazole

Fosfluconazole Structure
CAS No.
194798-83-9
Chemical Name:
Fosfluconazole
Synonyms
Prodif;CS-969;Fosfluconazol;Fosfluconazole(INN);Fosfluconazole, >=98%;Dihydrogen phosphate ester;Fungal,Inhibitor,Fosfluconazole,inhibit;2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propyl dihydrogen phosphate;PHARMA PRODUCT FLUCONAZOLE USP 2-(2,4-DIFLUOROPHENYL)-1,3-BIS(1,2,4-TRIAZOL-1-YL) PROPAN-2-OL;2-(2,4-Difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-yl dihydrogen phosphate (Efinaconazole?Impurity)
CBNumber:
CB71120322
Molecular Formula:
C13H13F2N6O4P
Molecular Weight:
386.25
MOL File:
194798-83-9.mol
MSDS File:
SDS
Modify Date:
2024/7/2 8:55:14

Fosfluconazole Properties

Melting point 223-224°
Boiling point 701.5±70.0 °C(Predicted)
Density 1.70±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 6.2 mg/mL (16.05 mM)
form Solid
pka 1.44±0.10(Predicted)
color White to off-white

Fosfluconazole Chemical Properties,Uses,Production

Description

Fosfluconazole is a phosphate prodrug of fluconazole, and it was launched in Japan as an intravenous injection for the treatment of candidiasis and cryptococcosis infections. Fluconazole, a triazole antifungal agent, is a selective inhibitor of fungal cytochrome P450 sterol C-14 alpha-demethylation, and it is widely used for the treatment of patients with serious systemic fungal infections. Fluconazole is marketed in both oral and intravenous formulations, the latter being a dilute (2 mg/ mL) infusion in saline due to the relatively poor water solubility of the drug. In patients needing high doses (>400 mg) of fluconazole, a drawback of the IV formulation is the requirement of a high-volume infusion, which is undesirable in critically ill patients in whom fluid overload must be avoided. Fosfluconazole is a prodrug with approximately 40-fold higher water solubility than fluconazole, thereby achieving a substantial reduction in infusion volume. It is prepared in three steps starting from fluconazole. In the first step, fluconazole is converted to its dibenzyl phosphite derivative by reaction with phosphorous trichloride and benzyl alcohol. Subsequent oxidation of the phosphite to the corresponding phosphate with hydrogen peroxide and cleavage of the benzyl protecting groups by hydrogenolysis affords fosfluconazole. In vitro, fosfluconazole is at least 25-fold less potent than fluconazole against single isolates of Candida species and Cryptococcus neoformans. In vivo, it is rapidly hydrolyzed to fluconazole by phosphatase enzymes and exhibits similar efficacy to fluconazole in experimental models of fungal disease. The hydrolysis potential of fosfluconazole was initially demonstrated in homogenates of kidney, lung and liver of rat, dog, and human. Subsequently, in clinical trials with healthy volunteers (n=24), fosfluconazole was shown to hydrolyze rapidly and almost completely to provide a 97% mean bioavailability of fluconazole. Less than 1% of the administered dose of fosfluconazole was excreted unchanged in the urine, with the majority (85.6%) of the dose eliminated as fluconazole. The terminal half-life was about 2.3 hours, and the volume of distribution was 0.2 L/kg. The time to reach steady state drug levels with 500 mg daily dose was about 10 days, which could be shortened to 3 days by administering loading doses of 1000 mgs on days 1 and 2 followed by 500 mg daily. Further studies showed that hepatic or renal impairment did not significantly alter the pharmacokinetic profile of fosfluconazole. In phase III studies in patients with deep-seated mycosis due to Candida or Cryptococcus (n=160), a 2-day loading dose regimen of fosfluconazole provided efficacy range of 73.8% (in Japanese patients) to 91.7% (patients of non-Japanese origin). The adverse events seen in these trials were similar to those previously known with fluconazole therapy and included rash (3.1%), abnormal liver function values (2.5%), asthma (1.9%), and lightheadedness (1.9%).

Originator

Pfizer (Japan)

brand name

Prodif

Fosfluconazole Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 96)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Sujata Chemicals +91-9898025496 +91-9898025496 Gujarat, India 73 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29900 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
Chongqing Chemdad Co., Ltd +86-023-6139-8061 +86-86-13650506873 China 39916 58 Inquiry
SIMAGCHEM CORP +86-13806087780 China 17367 58 Inquiry
Dayang Chem (Hangzhou) Co.,Ltd. 571-88938639 +8617705817739 China 52861 58 Inquiry
Hefei TNJ Chemical Industry Co.,Ltd. 0551-65418684 +8618949823763 China 25363 58 Inquiry
Hebei Duling International Trade Co. LTD +8617333973358 China 15437 58 Inquiry

194798-83-9(Fosfluconazole)Related Search:

2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propyl dihydrogen phosphate Prodif Fosfluconazole, >=98% PHARMA PRODUCT FLUCONAZOLE USP 2-(2,4-DIFLUOROPHENYL)-1,3-BIS(1,2,4-TRIAZOL-1-YL) PROPAN-2-OL Dihydrogen phosphate ester CS-969 Fosfluconazole(INN) 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)-, 1-(dihydrogen phosphate) 1H-1,2,4-Triazole-1-ethanol, a-(2,4-difluorophenyl)-a-(1H-1,2,4-triazol-1-ylmethyl)-,1-(dihydrogen phosphate) Fungal,Inhibitor,Fosfluconazole,inhibit 2-(2,4-Difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-yl dihydrogen phosphate (Efinaconazole?Impurity) Fosfluconazol 194798-83-9 C13H13F2N6O4P Amines API Chiral Reagents Heterocycles